Swiss National Bank Biogen Inc. Transaction History

Swiss National Bank

$143 Billion
Q2 2024

A detailed history of Swiss National Bank transactions in Biogen Inc. stock. As of the latest transaction made, Swiss National Bank holds 430,400 shares of BIIB stock, worth $74.8 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

430,400

Previous 433,900 0.81%

Holding current value

$74.8 Million

Previous $93.6 Million 6.64%

% of portfolio

0.07%

Previous 0.07%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 08, 2024	SELL	$190.52 - $236.72 $666,820 - $828,520	-3,500 Reduced 0.81%	430,400 $99.8 Million
Q1 2024 May 07, 2024	SELL	$212.02 - $267.71 $4.03 Million - $5.09 Million	-19,000 Reduced 4.2%	433,900 $93.6 Million
Q4 2023 Feb 06, 2024	SELL	$222.59 - $267.94 $2.83 Million - $3.4 Million	-12,700 Reduced 2.73%	452,900 $117 Million
Q3 2023 Nov 08, 2023	SELL	$253.3 - $285.89 $14.3 Million - $16.1 Million	-56,300 Reduced 10.79%	465,600 $120 Million
Q2 2023 Aug 09, 2023	SELL	$275.25 - $318.06 $13.7 Million - $15.8 Million	-49,600 Reduced 8.68%	521,900 $149 Million
Q1 2023 May 10, 2023	SELL	$256.56 - $292.34 $4.7 Million - $5.35 Million	-18,300 Reduced 3.1%	571,500 $159 Million
Q4 2022 Feb 08, 2023	SELL	$252.44 - $306.72 $11.4 Million - $13.8 Million	-44,972 Reduced 7.08%	589,800 $163 Million
Q3 2022 Nov 09, 2022	SELL	$194.69 - $268.46 $506,194 - $697,996	-2,600 Reduced 0.41%	634,772 $169 Million
Q2 2022 Aug 09, 2022	BUY	$187.54 - $223.02 $206,294 - $245,322	1,100 Added 0.17%	637,372 $130 Million
Q1 2022 May 09, 2022	BUY	$193.77 - $244.14 $13.5 Million - $17 Million	69,700 Added 12.3%	636,272 $134 Million
Q4 2021 Feb 08, 2022	SELL	$223.92 - $287.77 $6.43 Million - $8.26 Million	-28,700 Reduced 4.82%	566,572 $136 Million
Q3 2021 Nov 08, 2021	SELL	$282.99 - $369.05 $7.3 Million - $9.52 Million	-25,800 Reduced 4.15%	595,272 $168 Million
Q2 2021 Aug 06, 2021	BUY	$259.0 - $414.71 $7.59 Million - $12.2 Million	29,314 Added 4.95%	621,072 $215 Million
Q1 2021 May 07, 2021	SELL	$242.95 - $284.63 $1.51 Million - $1.76 Million	-6,200 Reduced 1.04%	591,758 $166 Million
Q4 2020 Feb 05, 2021	SELL	$236.26 - $355.63 $8.81 Million - $13.3 Million	-37,300 Reduced 5.87%	597,958 $146 Million
Q3 2020 Nov 09, 2020	SELL	$264.77 - $305.71 $14.1 Million - $16.3 Million	-53,200 Reduced 7.73%	635,258 $180 Million
Q2 2020 Aug 05, 2020	SELL	$258.66 - $342.55 $3.08 Million - $4.08 Million	-11,900 Reduced 1.7%	688,458 $184 Million
Q1 2020 May 08, 2020	BUY	$268.85 - $341.04 $31.9 Million - $40.5 Million	118,800 Added 20.43%	700,358 $222 Million
Q4 2019 Feb 06, 2020	SELL	$220.06 - $304.07 $12.9 Million - $17.9 Million	-58,800 Reduced 9.18%	581,558 $173 Million
Q3 2019 Nov 12, 2019	SELL	$217.44 - $243.88 $182,867 - $205,103	-841 Reduced 0.13%	640,358 $149 Million
Q2 2019 Aug 02, 2019	SELL	$219.29 - $241.72 $6.89 Million - $7.59 Million	-31,400 Reduced 4.67%	641,199 $150 Million
Q1 2019 May 10, 2019	BUY	$216.71 - $338.96 $3.86 Million - $6.03 Million	17,800 Added 2.72%	672,599 $159 Million
Q4 2018 Feb 13, 2019	SELL	$278.5 - $352.75 $5.26 Million - $6.67 Million	-18,900 Reduced 2.81%	654,799 $197 Million
Q3 2018 Nov 08, 2018	SELL	$293.51 - $383.83 $7.63 Million - $9.98 Million	-26,000 Reduced 3.72%	673,699 $238 Million
Q2 2018 Aug 09, 2018	BUY	$257.52 - $306.91 $5.46 Million - $6.51 Million	21,200 Added 3.12%	699,699 $203 Million
Q1 2018 May 04, 2018	SELL	$260.13 - $367.91 $26.6 Million - $37.7 Million	-102,400 Reduced 13.11%	678,499 $186 Million
Q4 2017 Feb 07, 2018	SELL	$307.64 - $344.58 $2.43 Million - $2.72 Million	-7,900 Reduced 1.0%	780,899 $249 Million
Q3 2017 Nov 03, 2017	BUY	$281.15 - $329.69 $222 Million - $260 Million	788,799	788,799 $247 Million

Others Institutions Holding BIIB

# of Institutions

1,018

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account

Swiss National Bank Biogen Inc. Transaction History